EANS-News: AGENNIX AG
Agennix AG to Present at Two Investor Conferences in
February
-------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. --------------------------------------------------------------------------------
Company Information/Presentation; Investor Conferences
Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and Houston, TX, January 26, 2011 - Agennix AG (Frankfurt Stock Exchange: AGX) today announced that the Company will be presenting at two investor conferences in February.
The Company will give a corporate presentation at the upcoming Close Brothers Seydler Bank AG Small and Mid Cap Conference. The presentation will be on Wednesday, February 2, 2011, at 15:40 CET at the IHK Frankfurt (Boerse), Frankfurt am Main, Germany.
Agennix will also give a presentation at the 13th Annual BIO CEO & Investor Conference in New York, NY, USA. The presentation is scheduled for Tuesday, February 15, 2011 at 9:00 AM ET/15:00 CET at The Waldorf Astoria Hotel. A live audio webcast will be available through the Agennix Web site at www.agennix.com. A replay will be available on the Web site following the live event.
Additionally, as part of the conference, Dr. Rajesh Malik, Chief Medical Officer of Agennix AG, will participate on a panel entitled, "Oncology: Lung Cancer - Clearing the Airways on New Treatments." The panel is scheduled for Monday, February 14, 2011 at 9:00 AM ET.
About Agennix Agennix AG is a publicly listed biopharmaceutical company that is focused on the development of novel therapies that have the potential to substantially improve the length and quality of life of critically ill patients in areas of major unmet medical need. The Company's most advanced program is talactoferrin, an oral therapy that has demonstrated activity in randomized, double-blind, placebo-controlled Phase II studies in non-small cell lung cancer, as well as in severe sepsis. Talactoferrin is currently in Phase III clinical trials in non-small cell lung cancer, and Agennix plans to develop this program further for the treatment of severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase I testing and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The Company has three sites of operation: Planegg/Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com.
This press release contains forward-looking statements, which express the current beliefs and expectations of the management of Agennix AG. Such statements are based on current expectations and are subject to risks and uncertainties, many of which are beyond our control, that could cause future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. Forward-looking statements speak only as of the date on which they are made and Agennix undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.
AgennixTM is a trademark of the Agennix group.
end of announcement euro adhoc --------------------------------------------------------------------------------
Further inquiry note:
Barbara Müller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com
In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com
Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu
Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com
Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade
Original-Content von: AGENNIX AG i.L., übermittelt durch news aktuell